Drug Trial Radar · NCT04617314
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Mar 10, 2021
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton in subjects with c-Met positive advanced malignant solid tumors.
Conditions
- Solid Tumor
Interventions
RC108Drug
RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: From the day of ICF signment to 28 days after the day of the last treatment
- Maximum Tolerated dose of RC108Time frame: 21 days after first treatment.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Hospital of Jilin University
Changchun, Jilin, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.